Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cassava Sciences, Inc. - Common Stock
(NQ:
SAVA
)
2.380
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cassava Sciences, Inc. - Common Stock
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
38
39
Next >
42 Stocks Moving In Wednesday's Mid-Day Session
↗
November 17, 2021
Gainers Sono Group N.V. (NASDAQ: SEV) shares jumped 66% to $24.90 after the company priced its IPO at $15 per share. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares climbed...
Via
Benzinga
Topics
Initial Public Offering
SAVA Stock Alert: The SEC Investigation That Has Cassava Sciences Cratering Today
↗
November 17, 2021
Cassava Sciences (SAVA) stock is on the move Wednesday as investors react to reports of an SEC investigation over possible data manipulation.
Via
InvestorPlace
Topics
Regulatory Compliance
Cassava Sciences In Hot Water Again As Shorts Claim 'Extreme' Data Manipulation
↗
November 17, 2021
In a filing, the short sellers claim the science backing Cassava's drug is impossible.
Via
Investor's Business Daily
Jim Cramer Likes This Stock Over Cassava Sciences And Biogen
↗
November 17, 2021
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cassava Sciences, Inc. (NASDAQ:
Via
Benzinga
Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15%
November 16, 2021
Palm Beach, FL –November 16, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy...
Via
FinancialNewsMedia
NASDAQ:SAVA Long Term Investor Notice: Investigation of Potential Wrongdoing at Cassava Sciences, Inc.
↗
November 15, 2021
San Diego, CA -- (SBWIRE) -- 11/15/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Cassava Sciences, Inc..
Via
SBWire
Topics
Lawsuit
Cassava Pops As Cortexyme Dives — Why One Alzheimer's Stock Is 'Back On Track'
↗
November 11, 2021
An analyst says Cassava is on track, but Cortexyme took another beating Thursday.
Via
Investor's Business Daily
7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside
↗
November 11, 2021
Here are seven of the top short-squeeze stocks investors may want to keep their eye on, as retail investors lay and wait for the next squeeze.
Via
InvestorPlace
Cassava Sciences Needs Time and Data to Prove Itself Before You Buy
↗
November 09, 2021
Even as SAVA stock whipsaws in both directions, Cassava's commitment to treating Alzheimer's disease remains as firm and steady as ever.
Via
InvestorPlace
Cassava Is a Sell After Accusations of Data Manipulation
↗
November 09, 2021
After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock.
Via
InvestorPlace
Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop
↗
November 08, 2021
Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.
Via
InvestorPlace
5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Cassava Sciences Joins Following Short Report
↗
November 08, 2021
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE:
Via
Benzinga
81 Biggest Movers From Yesterday
↗
November 05, 2021
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8...
Via
Benzinga
Why Did Cassava Sciences Stock Jump 49% Today?
↗
November 04, 2021
Journal of Neuroscience has informed Cassava Sciences Inc (NASDAQ: SAVA) that there is no evidence of data manipulation in an article published in July 2012...
Via
Benzinga
Mid-Afternoon Market Update: Nasdaq Jumps 150 Points; NeoPhotonics Shares Spike Higher
↗
November 04, 2021
Toward the end of trading Thursday, the Dow traded down 0.44% to 35,999.43 while the NASDAQ rose 0.97% to 15,964.55. The S&P also rose, gaining 0.30% to 4,674.44. The U.S. has...
Via
Benzinga
Topics
Stocks
Why Cassava Sciences Shares Are Rising
↗
November 04, 2021
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher after a review by the Journal of Neuroscience showed there is no evidence of data manipulation in a 2012 company...
Via
Benzinga
S&P 500, Nasdaq Nab More Intraday Highs, Dow Falls Triple Digits
↗
November 04, 2021
Stocks are mixed midday, with the Dow Jones Industrial Average down triple digits.
Via
Talk Markets
Topics
Stocks
SAVA Stock Alert: Why Cassava Sciences Is Rocketing 50% Higher Today
↗
November 04, 2021
Cassava Sciences just got good news. SAVA stock is soaring as the company celebrates the end of its manipulated data accusations.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
November 04, 2021
Gainers Evaxion Biotech (NASDAQ:EVAX) stock moved upwards by 157.5% to $16.74 during Thursday's regular session. Evaxion Biotech's stock is trading at a volume of...
Via
Benzinga
Mid-Day Market Update: Gold Rises 1.7%; Lightspeed Commerce Shares Plunge
↗
November 04, 2021
Midway through trading Thursday, the Dow traded down 0.25% to 36,068.78 while the NASDAQ rose 0.60% to 15,906.62. The S&P also rose, gaining 0.21% to 4,670.58. The U.S. has...
Via
Benzinga
Topics
Stocks
Cassava Stock Soars; Journal Finds No Proof Of Tampered Alzheimer's Data
↗
November 04, 2021
The journal that published a disputed paper from Cassava said Thursday it found no evidence of data manipulation, leading SAVA stock to soar.
Via
Investor's Business Daily
Mid-Morning Market Update: Markets Mixed; Moderna Lowers Covid-19 Vaccine Sales Outlook
↗
November 04, 2021
Following the market opening Thursday, the Dow traded down 0.20% to 36,086.70 while the NASDAQ rose 0.83% to 15,942.06. The S&P also rose, gaining 0.40% to 4,679.39. The U.S....
Via
Benzinga
Topics
Stocks
55 Stocks Moving In Thursday's Mid-Day Session
↗
November 04, 2021
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the...
Via
Benzinga
Cassava Sciences Is on a Bumpy Road to Multibagger Status
↗
November 03, 2021
Based on analyst estimates for the next ten years, SAVA stock could be worth three times more if its Alzheimer's drug succeeds.
Via
InvestorPlace
71 Biggest Movers From Yesterday
↗
November 03, 2021
Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales...
Via
Benzinga
SAVA Stock: 8 Things to Know as Cassava Sciences Rockets Higher
↗
November 02, 2021
As investors bet that Cassava Sciences is on the cusp of a breakthrough with its Alzheimer's treatment, SAVA stock is gaining.
Via
InvestorPlace
What's Up With Cassava Sciences Flying Today?
↗
November 02, 2021
Cassava Sciences Inc (NASDAQ: SAVA) shares are trading up Tuesday as traders were able to push the stock higher. The stock has been trending on social media sites such...
Via
Benzinga
Artificial Intelligence Could Be About To Replace Your Doctor
November 02, 2021
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Cassava Stock Could Jump More Than 200 Times
↗
November 01, 2021
Cassava's Alzheimer's drug appears backed by strong data and plenty of public support. That's a winning combination for SAVA stock.
Via
InvestorPlace
Cassava Sciences’ Stock Remains an Enigma
↗
November 01, 2021
Cassava Sciences has lost 26% for the month through Oct. 27. Entering October, SAVA stock looked to go on a big run. It did the opposite.
Via
InvestorPlace
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
38
39
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit